By John Comandari, Beyond Stem Cells (Littleton, CO) — Retatrutide is the most talked-about name in weight loss right now, and for good reason. Here’s an honest, science-grounded look at the next-generation triple agonist — including where it fits today and our cautions.
TL;DR
- Retatrutide is a triple agonist activating GLP-1, GIP, and glucagon receptors — the added glucagon action burns more calories.
- Phase 3 TRIUMPH-1 data show average loss up to ~28.3% (≈70 lbs) at the 12 mg dose — bariatric-surgery territory.
- It is investigational and not yet FDA-approved. Beyond Stem Cells is awaiting final approval to carry it.
- Best suited for severe obesity or patients who’ve plateaued on other medications.
- Call 1-833-720-7836 or visit Beyond Stem Cells to join the waitlist.
Quick Answer
Retatrutide is an investigational triple-hormone medication that produces bariatric-surgery-level weight loss by activating three pathways at once. It is not yet FDA-approved — Beyond Stem Cells is awaiting final FDA approval before offering it.
What Makes It a “Triple Agonist”?
Here’s the simple progression across the three medications:
- Semaglutide → targets GLP-1 only.
- Tirzepatide → targets GLP-1 + GIP.
- Retatrutide → targets GLP-1 + GIP + glucagon.
That third pathway — glucagon activation — increases energy expenditure, meaning your body burns more calories. Early Phase 2 evidence showed unprecedented average weight loss of up to 24.2% at 48 weeks, and Phase 3 data pushed even higher.
What the Trial Evidence Shows
| Trial | Key Result |
|---|---|
| TRIUMPH-1 (12 mg) | Avg. 28.3% weight reduction (~70.3 lbs); over 45% of participants lost ≥30% |
| TRANSCEND-T2D-1 (type 2 diabetes) | Up to 2.0% HbA1c reduction; up to 16.8% (37.3 lbs) loss at 40 weeks |
Notably, early reports suggest patients on Retatrutide still feel hunger cues but get full significantly faster — typically reporting early satiety and appetite suppression within the first 3 to 5 days, rather than appetite vanishing entirely.
My Honest Take: Promising, But Be Patient
Retatrutide produces results historically seen only with bariatric surgery — that’s genuinely exciting. But I’ll be straight with you: it is still in Phase 3 trials and not yet FDA-approved. It’s best suited for individuals with severe obesity or those who have plateaued on other medications. Until approval, the right move for most people is to start on a proven, available option like Tirzepatide. Compare your options in our GLP-1 weight loss guide.
Dosing & Monitoring (As Used in Trials)
Because it isn’t FDA-approved, Retatrutide has no commercial pharmacy price or standard dosing. Clinical trials use a “start low, go slow” titration via once-weekly subcutaneous injection:
- Initial dose: 2 mg once weekly for the first 4 weeks
- Titration: increased in 2–4 mg increments every 4 weeks (e.g., 4 mg → 6 mg → 9 mg)
- Maintenance: typically 4–12 mg weekly, with 8–9 mg often balancing maximum efficacy and tolerability
For reference, out-of-pocket costs for compounded or research versions have ranged from $300 to $1,500+ per month.
How to Get on the Waitlist
Beyond Stem Cells is awaiting final FDA approval to carry Retatrutide. In the meantime, we can build you a proven, supervised plan and notify you the moment it’s available. While you’re here, explore our broader medical weight management program. Call 1-833-720-7836 (24/7) or visit www.beyondstemcells.com.
This article is educational and not medical advice. Retatrutide is investigational and not FDA-approved. Trial figures reflect published research, not guaranteed results. Individual results vary.